Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Unknown 9Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 2Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cladribine × Lymphoid × Clear all
NCT01446900 2018-01-31

R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

European Institute of Oncology

Phase 2 Terminated
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡